Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 2
2006 2
2007 3
2008 6
2009 1
2010 4
2011 4
2012 4
2013 6
2014 5
2015 4
2016 9
2017 6
2018 11
2019 9
2020 9
2021 11
2022 17
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Results by year

Filters applied: . Clear all
Page 1
Patient-derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for the management of metastatic castration-resistant prostate cancer.
Kase AM, Gleba J, Miller JL, Miller E, Petit J, Barrett MT, Zhou Y, Parent EE, Cai H, Knight JA, Orme J, Reynolds J, Durham WF, Metz TM, Meurice N, Edenfield B, Alasonyalilar Demirer A, Bilgili A, Hickman PG, Pawlush ML, Marlow L, Wickland DP, Tan W, Copland JA. Kase AM, et al. Among authors: tan w. Mol Cancer Ther. 2024 Mar 6. doi: 10.1158/1535-7163.MCT-23-0296. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38442920
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma.
Beckermann KE, Patnaik A, Winer I, Tan W, Bashir B, Kyriakopoulos CE, Sweis RF, Chamberlain M, Rini BI. Beckermann KE, et al. Among authors: tan w. Invest New Drugs. 2024 Apr;42(2):179-184. doi: 10.1007/s10637-024-01419-1. Epub 2024 Feb 19. Invest New Drugs. 2024. PMID: 38372949 Clinical Trial.
A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis.
Mosalem O, Tan W, Bryce AH, Dronca RS, Childs DS, Pagliaro LC, Orme JJ, Kase AM. Mosalem O, et al. Among authors: tan w. Prostate Cancer Prostatic Dis. 2024 Feb 10. doi: 10.1038/s41391-024-00799-y. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38341460
Cancer Cachexia: ASCO Guideline Rapid Recommendation Update.
Roeland EJ, Bohlke K, Baracos VE, Smith TJ, Loprinzi CL; Cancer Cachexia Expert Panel. Roeland EJ, et al. J Clin Oncol. 2023 Sep 1;41(25):4178-4179. doi: 10.1200/JCO.23.01280. Epub 2023 Jul 12. J Clin Oncol. 2023. PMID: 37467399
118 results